CN106632372B - A kind of intermediate and its preparation method and application - Google Patents

A kind of intermediate and its preparation method and application Download PDF

Info

Publication number
CN106632372B
CN106632372B CN201610851108.0A CN201610851108A CN106632372B CN 106632372 B CN106632372 B CN 106632372B CN 201610851108 A CN201610851108 A CN 201610851108A CN 106632372 B CN106632372 B CN 106632372B
Authority
CN
China
Prior art keywords
compound
preparation
formulas
formula
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610851108.0A
Other languages
Chinese (zh)
Other versions
CN106632372A (en
Inventor
杨世琼
康立涛
李倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI BIOCOMPOUNDS CHEMLAB CO Ltd
Original Assignee
SHANGHAI BIOCOMPOUNDS CHEMLAB CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI BIOCOMPOUNDS CHEMLAB CO Ltd filed Critical SHANGHAI BIOCOMPOUNDS CHEMLAB CO Ltd
Priority to CN201610851108.0A priority Critical patent/CN106632372B/en
Publication of CN106632372A publication Critical patent/CN106632372A/en
Application granted granted Critical
Publication of CN106632372B publication Critical patent/CN106632372B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical technology fields, more particularly to a kind of intermediate and its preparation method and application.The present invention provides a kind of intermediate, and the structure of the intermediate is as shown in general formula I:I wherein, R1Selected from hydrogen, benzyl, t-butyldimethylsilyi or tert-butyldiphenylsilanyl;R2Selected from hydrogen, hydroxyl ,-OR3;R3Selected from acetyl group or p-toluenesulfonyl;X is selected from hydrogen, Br or Cl.Intermediate provided by the present invention with general formula I is used to prepare beraprost and its salt.

Description

A kind of intermediate and its preparation method and application
Technical field
The present invention relates to pharmaceutical technology fields, more particularly to a kind of intermediate and its preparation method and application.
Background technique
Beraprost (Beraprost) is a kind of prostacyclin (PGI2) derivative, in the secondary five of prostacyclin A phenyl ring in parallel, increases the stability of molecule in member ring.Beraprost sodium (Beraprost sodium) is anticoagulant The sodium-salt form of beraprost, be suitable for pulmonary hypertension, intermittent claudication caused by Chronic occlusive arterial disease, pain and The symptoms such as creeping chill.Beraprost sodium (English name: Beraprost sodium, trade name: Kai Na or moral are received, molecular formula: C24H29O5Molecular weight: 420.48) Na has structure shown in Formula V, chemical name are as follows: (±) -2,3,3a, 8b- tetrahydro -2- hydroxyl Base -1- (3- hydroxy-4-methyl -1- octene -6- alkynyl) -1H- cyclopentano [b] benzofuran -5- sodium butyrate.
Beraprost sodium, which is first, to be taken orally, and the prostacyclin analogs that chemical property is stable, small by blood The prostacyclin receptor of plate and vascular smooth muscle, activated adenyl cyclase increase intracellular cAMP concentration, inhibit Ca2+Stream Enter and thromboxane A2Generate etc., to play the role of antiplatelet and expansion blood vessel.Beraprost sodium is public by Hungary's Cino Da Pistoia English Department (Chinoin) and toray Co., Ltd. (Toray) develop respectively, with trade name it is triumphant that with De Na respectively in China City.People constantly rise the demand of the drug, domestic at present without the production of raw medicine, and only co-partnership company is from Japan and breast Tooth benefit import.So developing the preparation method an of beraprost sodium and its intermediate has very important meaning and valence Value.
Document Tetrahedron, 1999,55,2449-2474 report the side for preparing beraprost sodium and its intermediate Method, intermediate I, chemical name: 4- (trans- -3- methyl-1 of 4a, 5a, 10b- cis- -4a, 10c-, 4a, 5,5a, 10b, 10c- hexahydro Two dislike simultaneously [5,4-a] cyclopentano [b] benzofuran -7- base) butyric acid, synthetic route is as follows:
The synthetic line is to obtain lactone intermediate through grignard reaction with 3- aldehyde radical methyl propionate VII with starting material VI The mixture of VIII and hydroxy ester intermediate compound I X, then convert lactone VIII for this mixture, then hydrogenate, and amount to three-step reaction Key intermediate IV is obtained, the main ring structure of beraprost sodium is constructed.Wherein, 3- aldehyde radical methyl propionate VII is expensive, institute Containing ester group the reaction the poor easy generation side reaction of stable under alkaline conditions, in addition, also easy open loop obtains product lactone VIII To a part of hydroxy ester intermediate compound I X, it is unfavorable for the control of reaction.
EP00848856 reports the intermediate compound IV that another route prepares beraprost sodium, and synthetic route is as follows.
This method is raw material with 3a, 8b- cis-dihydro -3H-5- carboxyl -7- bromine cyclopentadiene [b] benzofuran, is needed Eight steps react the intermediate compound IV that beraprost sodium is prepared, and step is too long.
China Patent Publication No. CN1537107A and CN100347165C are reported using the methyl esters of intermediate compound IV as raw material system The method of standby beraprost and its sodium salt.China Patent Publication No. CN103509044A is also only reported with the centre containing protecting group The ester of body IV is the method that raw material prepares beraprost and its sodium salt, is not directed to the preparation side of the intermediate compound IV of beraprost sodium Method.
Summary of the invention
In view of the foregoing deficiencies of prior art, the purpose of the present invention is to provide a kind of intermediates and preparation method thereof And purposes, for solving the problems, such as one or more in the prior art.
In order to achieve the above objects and other related objects, first aspect present invention provides a kind of intermediate, the intermediate Structure as shown in general formula I:
Wherein, R1Selected from hydrogen, benzyl, t-butyldimethylsilyi or tert-butyldiphenylsilanyl;R2Selected from hydrogen, hydroxyl Base ,-OR3;R3Selected from acetyl group or p-toluenesulfonyl;X is selected from hydrogen, Br or Cl.
Preferably, the structure of the intermediate is as shown in general formula I-1:
Wherein, R1Selected from benzyl, t-butyldimethylsilyi or tert-butyldiphenylsilanyl;R2For hydroxyl;X is selected from Br or Cl.
It is highly preferred that the intermediate is selected from the group compound:
Preferably, the structure of the intermediate is as shown in general formula I-2:
Wherein, R1Selected from benzyl, t-butyldimethylsilyi or tert-butyldiphenylsilanyl;R3Selected from acetyl group or P-toluenesulfonyl;X is selected from Br or Cl.
It is highly preferred that the intermediate is selected from the group compound:
Preferably, the structural formula of the intermediate is as shown in Formulas I -3:
Wherein, R1For hydrogen;R2For hydrogen;X is hydrogen.
Second aspect of the present invention provides a kind of preparation method of -1 compound of Formulas I, by Formula II compound and formula III compound Under the effect of the catalyst, reaction prepares, and reaction equation is as follows:
Preferably, further include any one of following characteristics or multinomial:
A1) Formula II compound is dissolved in organic solvent, cooling, under inert gas protection, catalyst is added dropwise, is then added dropwise The organic solution of formula III compound, reaction prepare -1 compound of Formulas I;
A2) molar ratio of Formula II compound, catalyst and formula III compound is 1:1~1.2:1.2~3;
A3) volume ratio of organic solvent and Formula II compound is 8~15:1;
A4) catalyst is n-BuLi or s-butyl lithium;
A5) organic solvent is tetrahydrofuran, toluene or ether;
A6) organic solvent is tetrahydrofuran, toluene or ether in the organic solution of the formula III compound;
A7) temperature that is cooled to is -60~-80 DEG C;
A8 the reaction time is 10~30 minutes after catalyst) is added dropwise;
A9 the reaction time is 10~60 minutes after the organic solution of formula III compound) is added dropwise;
A10) further include -1 compound of Formulas I purification procedures: heat up after reaction, be added saturated ammonium chloride it is molten Then liquid is added water, and is extracted with ethyl acetate, separation obtains organic phase, after then using saturated common salt water washing, with anhydrous sulphur Sour sodium is dried, and filters, and is concentrated under reduced pressure, obtains -1 compound of Formulas I.
Third aspect present invention provides a kind of preparation method of -2 compound of Formulas I, by -1 compound of Formulas I through acetylation or right Tosylation prepares, and reaction equation is as follows:
Preferably, further include any one of following characteristics or multinomial:
B1) -1 compound of Formulas I is dissolved in organic solvent, and acylating agent is added, and adds 4-dimethylaminopyridine, reaction preparation Obtain -2 compound of Formulas I;
B2) molar ratio of -1 compound of Formulas I, organic solvent, acylating agent and 4-dimethylaminopyridine is 1:5~10:2~5: 0.1~2;
B3) organic solvent is pyridine;
B4) acylating agent is acetic anhydride or paratoluensulfonyl chloride;
B5) reaction temperature is 20~50 DEG C;
B6) reaction time is 8~24 hours;
B7) further include -2 compound of Formulas I purification procedures: cool down after reaction, water be added, and uses methylene chloride Extraction, separation obtain organic phase, then with after saturated common salt water washing, are dried with anhydrous sodium sulfate, filter, obtain Formulas I- 2 compounds.
Fourth aspect present invention provides a kind of preparation method of -3 compound of Formulas I, adds hydrogen to prepare by -2 compound for catalysis of Formulas I It obtains, reaction equation is as follows:
Preferably, further include any one of following characteristics or multinomial:
C1) -2 compound of Formulas I is dissolved in organic solvent, and anhydrous sodium acetate and catalyst is added, and hydrogen hydrogenation is added to prepare Obtain -3 compound of Formulas I;
C2) -2 compound of Formulas I, anhydrous sodium acetate, catalyst molar ratio be 1:2~5:0.1~0.5;
C3) organic solvent is selected from one of methanol, ethyl alcohol, isopropanol, ethyl acetate and tetrahydrofuran or a variety of;
C4) catalyst is 10% or 5% palladium carbon;
C5) reaction time is 3~18 hours;
C6) reaction relative pressure is 1~5MPa;
C7) further include -3 compound of Formulas I purification procedures: filter out catalyst after reaction, organic phase be concentrated, adds Enter water, and be extracted with ethyl acetate, separation obtains organic phase, then with after saturated common salt water washing, is carried out with anhydrous sodium sulfate It dries, filters, is concentrated under reduced pressure to give -3 compound of Formulas I.
Fifth aspect present invention provides a kind of preparation method of formula IV compound, including step d): by -3 compound oxygen of Formulas I Change prepares formula IV compound, and reaction equation is as follows:
Preferably, further include any one of following characteristics or multinomial:
D1) -3 compound of Formulas I is dissolved in acetonitrile and saturation potassium dihydrogen phosphate aqueous solution, and tetramethyl piperidine, secondary chlorine is added Acid sodium aqueous solution and sodium chlorite, reaction prepare formula IV compound;
D2) -3 compound of Formulas I, acetonitrile, potassium dihydrogen phosphate, tetramethyl piperidine, sodium hypochlorite sodium chlorite molar ratio be 1:5~20:5~20:0.1~0.5:1~3:1~3;
D3) concentration of aqueous sodium hypochlorite solution is 6~14.5%;
D4) concentration of sodium chlorite is 80~100%;
D5) reaction time is 1~5 hour;
D6) further include formula IV compound purification procedures: water is added after reaction, and is extracted with ethyl acetate, Separation obtains organic phase, then successively uses anhydrous sodium sulfate with after saturated sodium thiosulfate solution, water and saturated common salt water washing It is dried, filters, be concentrated under reduced pressure to give formula IV compound.
Preferably, the preparation method further includes following steps before step d):
Step a): under the effect of the catalyst by Formula II compound and formula III compound, reaction prepares the change of Formulas I -1 Object is closed, reaction equation is as follows:
It is highly preferred that further including any one of following characteristics or multinomial:
A1) Formula II compound is dissolved in organic solvent, cooling, under inert gas protection, catalyst is added dropwise, is then added dropwise The organic solution of formula III compound, reaction prepare -1 compound of Formulas I;
A2) molar ratio of Formula II compound, catalyst and formula III compound is 1:1~1.2:1.2~3;
A3) volume ratio of organic solvent and Formula II compound is 8~15:1;
A4) catalyst is n-BuLi, s-butyl lithium;
A5) organic solvent is tetrahydrofuran, toluene or ether;
A6) organic solvent is tetrahydrofuran, toluene or ether in the organic solution of the formula III compound;
A7) temperature that is cooled to is -60~-80 DEG C;
A8 the reaction time is 10~30 minutes after catalyst) is added dropwise;
A9 the reaction time is 10~60 minutes after the organic solution of formula III compound) is added dropwise;
A10) further include -1 compound of Formulas I purification procedures: heat up after reaction, be added saturated ammonium chloride it is molten Then liquid is added water, and is extracted with ethyl acetate, separation obtains organic phase, after then using saturated common salt water washing, with anhydrous sulphur Sour sodium is dried, and filters, and is concentrated under reduced pressure, obtains -1 compound of Formulas I;
Step b): preparing -2 compound of Formulas I through acetylation or tosylation for -1 compound of Formulas I, reaction Equation is as follows:
It is highly preferred that further including any one of following characteristics or multinomial:
B1) -1 compound of Formulas I is dissolved in organic solvent, and acylating agent is added, and adds 4-dimethylaminopyridine, reaction preparation Obtain -2 compound of Formulas I;
B2) molar ratio of -1 compound of Formulas I, organic solvent, acylating agent and 4-dimethylaminopyridine is 1:5~10:2~5: 0.1~2;
B3) organic solvent is pyridine;
B4) acylating agent is acetic anhydride or paratoluensulfonyl chloride;
B5) reaction temperature is 20~50 DEG C;
B6) reaction time is 8~24 hours;
B7) further include -2 compound of Formulas I purification procedures: cool down after reaction, water be added, and uses methylene chloride Extraction, separation obtain organic phase, then with after saturated common salt water washing, are dried with anhydrous sodium sulfate, filter, obtain Formulas I- 2 compounds;
Step c): hydrogen is added to prepare -3 compound of Formulas I -2 compound for catalysis of Formulas I, reaction equation is as follows:
It is highly preferred that further including any one of following characteristics or multinomial:
C1) -2 compound of Formulas I is dissolved in organic solvent, and anhydrous sodium acetate and catalyst is added, and hydrogen hydrogenation is added to prepare Obtain -3 compound of Formulas I;
C2) -2 compound of Formulas I, anhydrous sodium acetate, catalyst molar ratio be 1:2~5:0.1~0.5;
C3) organic solvent is selected from one of methanol, ethyl alcohol, isopropanol, ethyl acetate and tetrahydrofuran or a variety of;
C4) catalyst is 10% or 5% palladium carbon;
C5) reaction time is 3~18 hours;
C6) reaction relative pressure is 1~5MPa;
C7) further include -3 compound of Formulas I purification procedures: filter out catalyst after reaction, organic phase be concentrated, adds Enter water, and be extracted with ethyl acetate, separation obtains organic phase, then with after saturated common salt water washing, is carried out with anhydrous sodium sulfate It dries, filters, is concentrated under reduced pressure to give -3 compound of Formulas I.
Sixth aspect present invention provides above-mentioned intermediate and is used to prepare beraprost and its salt.
Preparation method through the invention obtains formula IV compound, then obtains beraprost by prior art preparation again And its salt, the prior art can refer to background technique Literature Tetrahedron, 1999,55,2449-2474, CN1537107A, CN100347165C and CN103509044A.Formula IV compound prepares beraprost and its salt by following reaction route:
Wherein, R4Selected from acetyl group, t-butyldimethylsilyi or tert-butyldiphenylsilanyl.
It is reacted under the effect of the catalyst by Formula II compound with formula III compound and prepares -1 compound of Formulas I, formula III compound replaces the ester group of VII with ehter bond group, and structure is more stable, and formula III compound is easily from cheap Isosorbide-5-Nitrae- Butanediol is made;It is reacted in preparation process and generates single product, it is stably and controllable, it is environmental-friendly, have yield good, process safety The features such as;When X=Cl, reaction selectivity is than document Tetrahedron, and X=Br is more preferable in 1999,55,2449-2474, obtains Product purity it is higher.Preparation method prepares through the invention intermediate compound IV yield and superior in quality, has stability The advantages that good, with high purity, convenient for storage.This patent is to adapt to new drug development, avoids the route of patent concentration, while being easy to carry out Polishing purification, easily prepared and each related impurities of control, optimize preparation process route, convenient for amplification.
Detailed description of the invention
Fig. 1 is shown as the formula IV compound that the embodiment of the present invention 13 is prepared1H-NMR spectrum.
Fig. 2 is shown as the mass spectrogram for the formula IV compound that the embodiment of the present invention 13 is prepared.
Specific embodiment
Illustrate embodiments of the present invention below by way of specific specific example, those skilled in the art can be by this specification Other advantages and efficacy of the present invention can be easily understood for disclosed content.The present invention can also pass through in addition different specific realities The mode of applying is embodied or practiced, the various details in this specification can also based on different viewpoints and application, without departing from Various modifications or alterations are carried out under spirit of the invention.
It should be clear that in the following example not specifically dated process equipment or device be all made of conventional equipment in the art or Device.
In addition, it should also be understood that, one or more method and step mentioned in the present invention does not repel before and after the combination step It can also be inserted into other methods step there may also be other methods step or between these explicitly mentioned steps, unless separately It is described;It should also be understood that the combination connection relationship between one or more equipment/device mentioned in the present invention is not repelled The two equipment/devices specifically mentioned before and after the unit equipment/device there may also be other equipment/device or at these it Between can also be inserted into other equipment/device, unless otherwise indicated.Moreover, unless otherwise indicated, the number of various method steps is only Identify the convenient tool of various method steps, rather than for the arrangement order of limitation various method steps or limits the enforceable model of the present invention It encloses, relativeness is altered or modified, and without material changes in technical content, when being also considered as, the present invention is enforceable Scope.
Embodiment 1.I-1 (R1=Bn, X=Cl) preparation
II (X=Cl) 14g (40.5mmol) is added in 500ml there-necked flask, dry tetrahydrofuran 140ml is added, it is cooling To -78 DEG C.Under nitrogen protection, the tetrahydrofuran solution (48.6mmol) of 19.5ml n-BuLi is slowly added dropwise into bottle, is added dropwise It finishes, -78 DEG C are continued stirring 20 minutes.Start the tetrahydrofuran solution that 10.8g 4- benzyloxy hydroxybutyraldehyde is added dropwise (60.75mmol), is added dropwise, and -78 DEG C are continued stirring 20 minutes, rises to -40 DEG C of dropwise addition 30ml saturated ammonium chloride solutions, stirs It mixes, is warmed to room temperature, water is added, is extracted with ethyl acetate 3 times, collect organic phase, washed organic phase 1 time with saturated common salt, it is organic Organic phase mutually is dried, filtered with anhydrous sodium sulfate and is concentrated under reduced pressure to give I-1 crude product, obtains I-1 14g after column chromatographic purifying, mole receipts Rate 78%, purity 95%.1H-NMR(CDCl3, 400MHz) and δ 1.35 (3H, d, J=5.2Hz, CH3), 1.67-1.98 (4H, m, 2CH2), 2.69-2.76 (1H, m, CH), 3.08-3.14 (1H, m, CH), 3.20 (1H, d, J=4.8Hz, OH), 3.36-3.55 (4H, m, 2CH2), 3.70 (1H, t, J=10.4Hz, CH), 4.38 (1H, dd, J=4.4,4.4Hz, CH), 4.47-4.50 (1H, M, CH), 4.52 (2H, d, J=2.4Hz, CH2), 4.69-4.79 (2H, m, CH2), 5.10-5.17 (1H, m, CH), 6.94 (1H, D, J=1.6Hz, ArH), 7.20 (1H, dd, J=2.4,2.4Hz, ArH), 7.27-7.37 (5H, m, ArH);MS (ESI, m/z): 445[M+H]+
Embodiment 2.I-1 (R1=TBS, X=Cl) preparation
II (X=Cl) 5.4g (15.6mmol) is added in 250ml there-necked flask, dry tetrahydrofuran 54ml is added, it is cooling To -78 DEG C.Under nitrogen protection, the tetrahydrofuran solution (18.7mmol) of 7.5ml n-BuLi is slowly added dropwise into bottle, drips Finish, -78 DEG C are continued stirring 20 minutes.Start the tetrahydrofuran solution that 4.7g 4- tert-butyl diformazan silicon oxygen hydroxybutyraldehyde is added dropwise (23.4mmol), is added dropwise, and -78 DEG C are continued stirring 20 minutes, rise to -40 DEG C of dropwise addition 10ml saturated ammonium chloride solutions, stirs, It is warmed to room temperature, water is added, is extracted with ethyl acetate 3 times, collect organic phase, washed organic phase 1 time with saturated common salt, organic phase is used Anhydrous sodium sulfate dries, filters organic phase and is concentrated under reduced pressure to give I-1 crude product, obtains I-1 5.4g, molar yield after column chromatographic purifying 73%, purity 95%.1H-NMR(CDCl3, 400MHz) and δ 0.07-0.09 (6H, m, 2CH3), 0.91-0.92 (9H, m, 3CH3), 1.36 (3H, d, J=4.8Hz, CH3), 1.60-1.69 (2H, m, CH2), 1.74-1.98 (4H, m, 2CH2), 2.70-2.77 (1H, M, CH), 3.09-3.15 (1H, m, CH), 3.37-3.46 (1H, m, CH), 3.52 (1H, d, J=4.8Hz, OH), 3.63-3.74 (3H, m, CH+CH2), 4.39 (1H, dd, J=4.4,7.6Hz, CH), 4.70-4.82 (2H, m, CH2), 5.11-5.18 (1H, m, CH), 6.94 (1H, m, ArH), 7.22-7.27 (1H, m, ArH);MS (ESI, m/z): 469 [M+H]+
Embodiment 3.I-1 (R1=TBS, X=Br) preparation
II (X=Br) 3.2g (8.2mmol) is added in 100ml there-necked flask, dry tetrahydrofuran 32ml is added, it is cooling To -78 DEG C.Under nitrogen protection, the tetrahydrofuran solution (9.8mmol) of 3.9ml n-BuLi is slowly added dropwise into bottle, drips Finish, -78 DEG C are continued stirring 20 minutes.Start the tetrahydrofuran solution that 2.5g 4- tert-butyl diformazan silicon oxygen hydroxybutyraldehyde is added dropwise (12.3mmol), is added dropwise, and -78 DEG C are continued stirring 20 minutes, rise to -40 DEG C of dropwise addition 10ml saturated ammonium chloride solutions, stirs, It is warmed to room temperature, water is added, is extracted with ethyl acetate 3 times, collect organic phase, washed organic phase 1 time with saturated common salt, organic phase is used Anhydrous sodium sulfate dries, filters organic phase, is concentrated under reduced pressure to give I-1 crude product, obtains I-1 2.4g, molar yield after column chromatographic purifying 57%, purity 95%.1H-NMR(CDCl3, 400MHz) and δ 0.07-0.09 (6H, m, 2CH3), 0.91-0.92 (9H, m, 3CH3), 1.36 (3H, d, J=4.8Hz, CH3), 1.60-1.69 (2H, m, CH2), 1.74-1.98 (4H, m, 2CH2), 2.70-2.77 (1H, M, CH), 3.09-3.15 (1H, m, CH), 3.37-3.46 (1H, m, CH), 3.52 (1H, d, J=4.8Hz, OH), 3.63-3.74 (3H, m, CH+CH2), 4.39 (1H, dd, J=4.4,7.6Hz, CH), 4.70-4.82 (2H, m, CH2), 5.11-5.18 (1H, m, CH), 6.94 (1H, m, ArH), 7.22-7.27 (1H, m, ArH);MS (ESI, m/z): 515 [M+H]+
Embodiment 4.I-1 (R1=TBDPS, X=Cl) preparation
II (X=Cl) 2.2g (6.4mmol) is added in 100ml there-necked flask, dry tetrahydrofuran 22ml is added, it is cooling To -78 DEG C.Under nitrogen protection, the tetrahydrofuran solution (7.6mmol) of 3.05ml n-BuLi is slowly added dropwise into bottle, drips Finish, -78 DEG C are continued stirring 20 minutes.Start the tetrahydrofuran solution that 3.11g 4- tert-butyl diphenyl silicon oxygen hydroxybutyraldehyde is added dropwise (9.5mmol), is added dropwise, and -78 DEG C are continued stirring 20 minutes, rise to -40 DEG C of dropwise addition 10ml saturated ammonium chloride solutions, stirs, It is warmed to room temperature, water is added, is extracted with ethyl acetate 3 times, collect organic phase, washed organic phase 1 time with saturated common salt, organic phase is used Anhydrous sodium sulfate dries, filters organic phase, is concentrated under reduced pressure to give I-1 crude product, obtains I-1 2.82g after column chromatographic purifying, mole receipts Rate 75%, purity 95%.1H-NMR (CDCl3,400MHz) δ 0.91-0.92 (9H, m, 3CH3), 1.36 (3H, d, J=4.8Hz, CH3), 1.60-1.69 (2H, m, CH2), 1.74-1.98 (4H, m, 2CH2), 2.70-2.77 (1H, m, CH), 3.09-3.15 (1H, m, CH), 3.37-3.46 (1H, m, CH), 3.52 (1H, d, J=4.8Hz, OH), 3.63-3.74 (3H, m, CH+CH2), 4.39 (1H, dd, J=4.4,7.6Hz, CH), 4.70-4.82 (2H, m, CH2), 5.11-5.18 (1H, m, CH), 6.94-7.59 (12H, m, ArH);MS (ESI, m/z): 593 [M+H]+.
Embodiment 5.I-2 (R1=Bn, R3=Ac, X=Cl) preparation
I-1 14g is added in 100ml single port bottle (31.5mmol comes from embodiment 1);Pyridine 84ml, under nitrogen protection, to DMAP 1.15g (9.5mmol) is added in bottle, acetic anhydride 9.65g (94.6mmol) is warming up to 40 DEG C and stirs 3 hours.It is down to room Temperature is added water, is extracted with dichloromethane 3 times, collects organic phase, is washed organic phase 1 time with saturated common salt, the anhydrous sulphur of organic phase Sour sodium dries, filters organic phase, and I-2 14.9g, molar yield 97.2%, purity 90%, without purifying are obtained after reduced pressure Directly carry out next step reaction.1H-NMR(CDCl3, 400MHz) and δ 1.35 (3H, d, J=5.2Hz, CH3), 1.67-1.98 (4H, M, 2CH2), 2.19 (3H, s, CH3), 2.69-2.76 (1H, m, CH), 3.08-3.14 (1H, m, CH), 3.36-3.55 (4H, m, 2CH2), 3.70 (1H, t, J=10.4Hz, CH), 4.38 (1H, dd, J=4.4,4.4Hz, CH), 4.47-4.50 (1H, m, CH), 4.52 (2H, d, J=2.4Hz, CH2), 4.69-4.79 (2H, m, CH2), 5.10-5.17 (1H, m, CH), 6.94 (1H, d, J= 1.6Hz, ArH), 7.20 (1H, dd, J=2.4,2.4Hz, ArH), 7.27-7.37 (5H, m, ArH);MS (ESI, m/z): 487 [M +H]+
Embodiment 6.I-2 (R1=TBS, R3=Ac, X=Cl) preparation
I-1 5.4g is added in 100ml single port bottle (11.5mmol comes from embodiment 2);Pyridine 32.4ml, nitrogen protection Under, DMAP 0.28g (2.2mmol) is added into bottle, acetic anhydride 3.5g (34.5mmol) is warming up to 40 DEG C and stirs 3 hours.Drop To room temperature, water is added, is extracted with dichloromethane 3 times, collect organic phase, is washed organic phase 1 time with saturated common salt, organic phase nothing Aqueous sodium persulfate dries, filters organic phase, and I-2 5.8g, molar yield 95.2%, purity 90%, without pure are obtained after reduced pressure Change and directly carries out next step reaction.1H-NMR(CDCl3, 400MHz) and δ 0.07-0.09 (6H, m, 2CH3), 0.91-0.92 (9H, m, 3CH3), 1.36 (3H, d, J=4.8Hz, CH3), 1.60-1.69 (2H, m, CH2), 1.74-1.98 (4H, m, 2CH2), 2.19 (3H, s, CH3), 2.70-2.77 (1H, m, CH), 3.09-3.15 (1H, m, CH), 3.37-3.46 (1H, m, CH), 3.63-3.74 (3H, m, CH+CH2), 4.39 (1H, dd, J=4.4,7.6Hz, CH), 4.70-4.82 (2H, m, CH2), 5.11-5.18 (1H, m, CH), 6.94 (1H, m, ArH), 7.22-7.27 (1H, m, ArH);MS (ESI, m/z): 511 [M+H]+
Embodiment 7.I-2 (R1=TBS, R3=Ts, X=Br) preparation
I-1 2.4g is added in 100ml single port bottle (4.7mmol comes from embodiment 3);Methylene chloride 24ml, to toluene sulphur Acyl chlorides 0.94g (4.9mmol) under nitrogen protection, is added dropwise triethylamine 1.4g (14mmol) into bottle, stirs 12 hours at room temperature, Water is added, is extracted with dichloromethane 3 times, collects organic phase, is washed organic phase 1 time with saturated common salt, organic phase anhydrous slufuric acid Sodium dries, filters organic phase, and I-2 2.93g, molar yield 94%, purity 90%, without purifying directly are obtained after reduced pressure Carry out next step reaction.1H-NMR(CDCl3, 400MHz) and δ 0.07-0.09 (6H, m, 2CH3), 0.91-0.92 (9H, m, 3CH3), 1.36 (3H, d, J=4.8Hz, CH3), 1.60-1.69 (2H, m, CH2), 1.74-1.98 (4H, m, 2CH2), 2.43 (3H, s, CH3), 2.70-2.77 (1H, m, CH), 3.09-3.15 (1H, m, CH), 3.37-3.46 (1H, m, CH), 3.63-3.74 (3H, m, CH+CH2), 4.39 (1H, dd, J=4.4,7.6Hz, CH), 4.70-4.82 (2H, m, CH2), 5.11-5.18 (1H, m, CH), (6.94-7.75 6H, m, ArH);MS (ESI, m/z): 667 [M+H]+
Embodiment 8.I-2 (R1=TBDPS, R3=Ts, X=Cl) preparation
I-1 2.82g is added in 100ml single port bottle (4.8mmol comes from embodiment 4);Methylene chloride 28ml, to toluene sulphur Acyl chlorides 0.94g (4.9mmol) under nitrogen protection, is added dropwise triethylamine 1.4g (14mmol) into bottle, stirs 12 hours at room temperature, Water is added, is extracted with dichloromethane 3 times, collects organic phase, is washed organic phase 1 time with saturated common salt, organic phase anhydrous slufuric acid Sodium dries, filters organic phase, and I-2 3.33g, molar yield 94%, purity 90%, without purifying directly are obtained after reduced pressure Carry out next step reaction.1H-NMR(CDCl3, 400MHz) and 0.91-0.92 (9H, m, 3CH3), 1.36 (3H, d, J=4.8Hz, CH3), 1.60-1.69 (2H, m, CH2), 1.74-1.98 (4H, m, 2CH2), 2.43 (3H, s, CH3), 2.70-2.77 (1H, m, CH), 3.09-3.15 (1H, m, CH), 3.37-3.46 (1H, m, CH), 3.63-3.74 (3H, m, CH+CH2), 4.39 (1H, dd, J =4.4,7.6Hz, CH), 4.70-4.82 (2H, m, CH2), 5.11-5.18 (1H, m, CH), 6.94-7.75 (16H, m, ArH); MS (ESI, m/z): 747 [M+H]+
Embodiment 9.I-3 (R1=Bn, R3=Ac, X=Cl) preparation
I-2 14.5g is added in 500ml high-pressure hydrogenation kettle (29.6mmol comes from embodiment 5);Anhydrous sodium acetate 4.9g(59.2mmol);10% palladium carbon hydrogenation catalyst 3.6g (2.9mmol, it is aqueous 60%);Methanol 140ml.Pressure limit: 1 ~5MPa is stirred 5 hours at room temperature, filters out palladium carbon, and organic phase is concentrated, and water is added, is extracted with ethyl acetate 3 times, is collected organic Phase is washed organic phase 1 time with saturated common salt, and organic phase dries, filters organic phase with anhydrous sodium sulfate, obtains I- after reduced pressure 3 8.1g, molar yield 90%, purity 98%.1H-NMR(CDCl3, 400MHz) and δ 1.36 (3H, d, J=5.2Hz, CH3), 1.56-2.06 (7H, m, CH2), 2.59 (2H, t, J=7.6Hz, CH2), 2.71-2.78 (1H, m, CH), 3.13-3.18 (1H, m, CH), 3.39-3.46 (1H, m, CH), 3.64-3.75 (3H, m, CH2), 4.39 (1H, dd, J=4.4,4.0Hz, CH), 4.71- 4.74 (1H, m, OH), 5.08-5.13 (1H, m, CH), 6.77 (1H, t, J=8.0Hz, ArH), 6.93 (1H, d, J=7.2Hz, ArH), 6.97 (1H, d, J=7.6Hz, ArH);MS (ESI, m/z): 305 [M+H]+
Embodiment 10.I-3 (R1=TBS, R3=Ac, X=Cl) preparation
I-2 5.8g is added in 250ml high-pressure hydrogenation kettle (11.3mmol comes from embodiment 6);Anhydrous sodium acetate 1.9g(22.7mmol);10% palladium carbon hydrogenation catalyst 1.5g (1.1mmol, it is aqueous 60%);Methanol 60ml.Pressure limit: 1~ 5MPa is stirred 5 hours at room temperature, filters out palladium carbon, and organic phase is concentrated, and water is added, is extracted with ethyl acetate 3 times, collects organic phase, It is washed organic phase 1 time with saturated common salt, organic phase dries, filters organic phase with anhydrous sodium sulfate, obtains after reduced pressure colourless Tetrahydrofuran 60ml is added in grease;Tetrabutyl ammonium fluoride 5.9g (22.6mmol), is stirred overnight at room temperature.Water is added, uses second Acetoacetic ester extracts 3 collection organic phases, is washed organic phase 1 time with saturated common salt, organic phase has been dried, filtered with anhydrous sodium sulfate Machine phase obtains I-3 3g, molar yield 87%, purity 98% after reduced pressure.1H-NMR(CDCl3, 400MHz) δ 1.36 (3H, D, J=5.2Hz, CH3), 1.56-2.06 (7H, m, CH2), 2.59 (2H, t, J=7.6Hz, CH2), 2.71-2.78 (1H, m, CH), 3.13-3.18 (1H, m, CH), 3.39-3.46 (1H, m, CH), 3.64-3.75 (3H, m, CH2), 4.39 (1H, dd, J= 4.4,4.0Hz, CH), 4.71-4.74 (1H, m, OH), 5.08-5.13 (1H, m, CH), 6.77 (1H, t, J=8.0Hz, ArH), 6.93 (1H, d, J=7.2Hz, ArH), 6.97 (1H, d, J=7.6Hz, ArH);MS (ESI, m/z): 305 [M+H]+
The preparation of embodiment 11.I-3 (R1=TBS, R3=Ts, X=Br)
I-2 2.93g is added in 100ml high-pressure hydrogenation kettle (4.4mmol comes from embodiment 7);Anhydrous sodium acetate 0.7g(8.8mmol);10% palladium carbon hydrogenation catalyst 0.7g (1.1mmol, it is aqueous 60%);Methanol 30ml.Pressure limit: 1~ 5MPa is stirred 5 hours at room temperature, filters out palladium carbon, and organic phase is concentrated, and water is added, is extracted with ethyl acetate 3 times, collects organic phase, It is washed organic phase 1 time with saturated common salt, organic phase dries, filters organic phase with anhydrous sodium sulfate, obtains after reduced pressure colourless Tetrahydrofuran 30ml is added in grease;Tetrabutyl ammonium fluoride 2.3g (8.8mmol), is stirred overnight at room temperature.Water is added, uses second Acetoacetic ester extracts 3 collection organic phases, is washed organic phase 1 time with saturated common salt, organic phase has been dried, filtered with anhydrous sodium sulfate Machine phase obtains I-3 1.16g, molar yield 87%, purity 98% after reduced pressure.1H-NMR(CDCl3, 400MHz) and δ 1.36 (3H, d, J=5.2Hz, CH3), 1.56-2.06 (7H, m, CH2), 2.59 (2H, t, J=7.6Hz, CH2), 2.71-2.78 (1H, M, CH), 3.13-3.18 (1H, m, CH), 3.39-3.46 (1H, m, CH), 3.64-3.75 (3H, m, CH2), 4.39 (1H, dd, J =4.4,4.0Hz, CH), 4.71-4.74 (1H, m, OH), 5.08-5.13 (1H, m, CH), 6.77 (1H, t, J=8.0Hz, ArH), 6.93 (1H, d, J=7.2Hz, ArH), 6.97 (1H, d, J=7.6Hz, ArH);MS (ESI, m/z): 305 [M+H]+
The preparation of embodiment 12.I-3 (R1=TBDPS, R3=Ts, X=Cl)
I-2 3.33g is added in 100ml high-pressure hydrogenation kettle (4.4mmol comes from embodiment 8);Anhydrous sodium acetate 0.7g(8.8mmol);10% palladium carbon hydrogenation catalyst 0.7g (1.1mmol, it is aqueous 60%);Methanol 30ml.Pressure limit: 1~ 5MPa is stirred 5 hours at room temperature, filters out palladium carbon, and organic phase is concentrated, and water is added, is extracted with ethyl acetate 3 times, collects organic phase, It is washed organic phase 1 time with saturated common salt, organic phase dries, filters organic phase with anhydrous sodium sulfate, obtains after reduced pressure colourless Tetrahydrofuran 30ml is added in grease;Tetrabutyl ammonium fluoride 2.3g (8.8mmol), is stirred overnight at room temperature.Water is added, uses second Acetoacetic ester extracts 3 collection organic phases, is washed organic phase 1 time with saturated common salt, organic phase has been dried, filtered with anhydrous sodium sulfate Machine phase obtains I-3 1.0g, molar yield 75%, purity 98% after reduced pressure.1H-NMR(CDCl3, 400MHz) and δ 1.36 (3H, d, J=5.2Hz, CH3), 1.56-2.06 (7H, m, CH2), 2.59 (2H, t, J=7.6Hz, CH2), 2.71-2.78 (1H, M, CH), 3.13-3.18 (1H, m, CH), 3.39-3.46 (1H, m, CH), 3.64-3.75 (3H, m, CH2), 4.39 (1H, dd, J =4.4,4.0Hz, CH), 4.71-4.74 (1H, m, OH), 5.08-5.13 (1H, m, CH), 6.77 (1H, t, J=8.0Hz, ArH), 6.93 (1H, d, J=7.2Hz, ArH), 6.97 (1H, d, J=7.6Hz, ArH);MS (ESI, m/z): 305 [M+H]+
Embodiment 13.IV:4- (trans- -3- methyl-1 of 4a, 5a, 10b- cis- -4a, 10c-, 4a, 5,5a, 10b, 10c- six Hydrogen two dislikes simultaneously [5,4-a] cyclopentano [b] benzofuran -7- base) preparation of butyric acid
I-3 12g (39.5mmol) is added in 1L single port bottle, acetonitrile 200ml is saturated potassium dihydrogen phosphate aqueous solution 200ml, TEMPO 0.74g (4.7mmol), 14.5% aqueous sodium hypochlorite solution 28.4ml (55.3mmol), 80% sodium chlorite 8.9g (79mmol).It stirs 3 hours at room temperature.Water is added, stirring is added ethyl acetate and extracts 3 times, collect organic phase, saturation is added Hypo solution cleans 1 time, and water is added and cleans 1 time, and saturated salt solution cleans 1 time, and organic phase is dry with anhydrous sodium sulfate, Organic phase is filtered, intermediate compound IV 11g, molar yield 91%, purity 97% are obtained after reduced pressure.1H-NMR(CDCl3, 400MHz) 1.36 (3H, d, J=5.2Hz, CH of δ3), 1.80-2.05 (4H, m, 2CH2), 2.37 (2H, t, J=15.2Hz, CH2), 2.56-2.66 (2H, m, CH2), 2.70-2.77 (1H, m, CH), 3.13-3.18 (1H, m, CH2), 3.39-3.46 (1H, m, CH2), 3.68-3.75 (1H, m, CH), 4.41 (1H, dd, J=4.4,4.4Hz, CH), 4.71-4.75 (1H, m, CH), 5.08- 5.13 (1H, m, CH), 6.76-6.80 (1H, m, ArH), 6.90-6.98 (2H, m, ArH);MS (ESI, m/z): 317 [M-H]-
The preparation of embodiment 14. V
IV 11g (34.6mmol comes from embodiment 13), DMF110ml, potassium carbonate 14.32g are added in 250ml single port bottle (103.7mmol) and iodomethane 9.8g (69.18mmol).It stirs 3 hours at room temperature, water is added, ethyl acetate extracts anhydrous sulphur It is concentrated to give V crude product after sour sodium is dry, column purification is crossed and obtains white solid: 10.5g, molar yield: 91.6%, purity: 94%.1H-NMR(CDCl3, 400MHz) and δ 1.86-2.17 (5H, m, 2CH2+ OH), 2.30-2.34 (2H, m, CH2), 2.51-2.63 (4H, M, CH2+ CH+OH), 3.41-3.45 (1H, m, CH2), 3.67 (3H, s, CH3), 3.68-3.78 (1H, m, CH2), 3.86-3.90 (1H, m, CH), 4.08-4.14 (1H, m, CH), 5.13-5.18 (1H, m, CH), 6.93 (1H, t, J=7.2Hz, ArH), 7.21- 7.28 (2H, m, ArH);MS (ESI, m/z): 333 [M+H]-
The preparation of embodiment 15. VI
V 10.5g (31.6mmol comes from embodiment 14), methanol 100ml, 1M HCl are added in 250ml single port bottle 15ml is stirred 5 hours at room temperature, and methanol is concentrated, and water is added, and ethyl acetate extraction is concentrated after anhydrous sodium sulfate is dry.It is pure to cross column Change obtains VI 9.6g.Molar yield: 99%, purity: 95%.1H-NMR(CDCl3, 400MHz) δ 1.37 (3H, d, J=5.2Hz, CH3), 1.81-2.00 (4H, m, 2CH2), 2.31-2.35 (2H, m, CH2), 2.55-2.63 (2H, m, CH2), 2.71-2.78 (1H, m, CH), 3.13-3.18 (1H, m, CH2), 3.40-3.47 (1H, m, CH2), 3.66 (3H, s, CH3), 3.67-3.76 (1H, M, CH), 4.39-4.42 (1H, m, CH), 4.71-4.75 (1H, m, CH), 5.08-5.14 (1H, m, CH), 6.78 (1H, t, J= 7.2Hz, ArH), 6.90-6.98 (2H, m, ArH);MS (ESI, m/z): 333 [M+H]-
16. VII (R of embodiment4=Ac) preparation
V 1.74g (5.68mmol comes from embodiment 15) is added in 250ml single port bottle and is dissolved in the dry tetrahydrofuran of 25ml In, dry triethylamine 2.86mL (20.4mmol) and triphenylchloromethane 2.87g (10.29mmol) is added, is stirred at 60 DEG C React 6h.Acetic anhydride 7.41mL (78.4mmol) is added after being cooled to room temperature and refines pyridine 5.9mL (73.3mmol), at 50 DEG C It is stirred to react 14h.Ice bath is cooling, and the methanol hydrochloride solution tune pH to 1 of 15mL3.7mol/L is added dropwise, and reaction 6h is stirred at room temperature.Ice Under bath, it is slowly added to sodium bicarbonate 1g tune pH to 6, is concentrated, water, dilute hydrochloric acid, saturated common salt washing are successively used in ethyl acetate dissolution It washs, anhydrous sodium sulfate dries, filters, and after concentration, is purified by silica gel column chromatography to obtain VII 1.19g of colorless oil compound, mole receipts Rate: 60.1%.Purity 97%.1H-NMR(CDCl3, 400MHz): δ 1.83 (3H, s, CH3), 1.92-1.96 (2H, m, CH2), 2.20-2.29 (2H, m, CH2), 2.33-2.36 (2H, m, CH2), 2.53-2.63 (3H, m, CH2+ CH), 3.66 (4H, m, CH3+ CH), 3.67-3.72 (2H, m, CH2), 5.05-5.09 (1H, m, CH), 5.17-5.22 (1H, m, CH), 6.77 (1H, t, J= 8.0Hz, ArH), 6.94 (1H, d, J=8.0Hz, ArH), 7.03 (1H, d, J=8.0Hz, ArH);MS (ESI, m/z): 349 [M+ H]+
17. Ⅸ (R of embodiment4=Ac) preparation
In 100ml single port bottle, VII 1.19g of compound (3.4mmol, from embodiment 16) is dissolved in the tetrahydro of 20mL purification It in furans, sequentially adds dimethyl sulfoxide 3.65mL (51.4mmol), pyridine 55.5 μ L (0.69mmol), 51.5 μ L of trifluoroacetic acid (0.69mmol) and DCC 0.85g (4.13mmol), nitrogen protection are stirred to react 10h at room temperature, chemical combination are added after ice bath is cooling The tetrahydrofuran solution 15mL of VIII 1.065g of object (4.59mmol) and 60%NaH 178mg (4.45mmol) are stirred under ice bath anti- 10min is answered, is warmed to room temperature, 3h is stirred to react.Acetic acid 0.26mL tune pH to 6 is added dropwise in mixture, and 50mL ethyl acetate is added in concentration Dissolution, saturated common salt water washing, anhydrous sodium sulfate dries, filters, and after concentration, is purified by silica gel column chromatography to obtain colorless oil chemical combination Object 1.1g, molar yield: 71.16%, purity: 97%.1H-NMR (400MHz, CDCl3) δ 1.21 (3H, d, J=7.6Hz, CH3), 1.76-1.78 (6H, m, CH3+CH2+ CH), 1.90-1.98 (2H, m, CH2), 2.13-2.17 (1H, m, CH2), 2.26 (1H, dd, J=6.0Hz, 16.4Hz, CH2), 2.35 (2H, t, J=7.6Hz, CH2), 2.56-2.59 (1H, m, CH), 2.60- 2.67 (3H, m, CH2+ CH), 2.90-2.97 (2H, m, CH2), 3.66 (3H, s, CH3), 3.66-3.69 (1H, m, CH), 4.99- 5.02 (1H, m, CH), 5.23-5.24 (1H, m, CH), 6.29 (1H, dd, J=5.6Hz, 15.6Hz, CH), 6.75-6.86 (2H, M, ArH), 6.94-6.97 (2H, m, ArH);MS (ESI, m/z): 453 [M+H]+
The preparation of embodiment 18. Ⅹ
In 100ml single port bottle, by Ⅸ 600mg of compound (1.33mmol comes from embodiment 17) and cerium chloride seven-hydrate 737mg (1.97mmol) is dissolved in 50mL methanol, and sodium borohydride 73.7mg (1.97mmol) is added at 0 DEG C, after being stirred to react 30min, adds Enter saturated sodium bicarbonate solution 10mL, is stirred to react 30min at 0 DEG C.100mL ethyl acetate, saturated common salt is added in filtering, concentration Water washing, anhydrous sodium sulfate dry, filter, and after concentration, are purified by silica gel column chromatography to obtain colorless oil mixture 574mg.It is dissolved in 50mL is refined in methanol, and the methanol solution of 200 μ L1.8mol/L sodium methoxides is added.It is stirred to react 8h at room temperature, 25 μ L are added 50mL ethyl acetate, saturated common salt water washing is added in CH3COOH tune pH to 7 after concentration, anhydrous sodium sulfate dries, filters, and is concentrated Afterwards, it is purified by silica gel column chromatography to obtain Ⅹ 240mg of oily compound, molar yield: 43.9%, purity 99%.1H NMR(CDCl3, 400MHz): δ 0.98-1.02 (3H, m, CH3), 1.74-1.79 (4H, m, CH3+ CH), 1.90-2.12 (4H, m, 2CH2), 2.24- 2.25 (1H, m, CH), 2.32 (2H, t, J=7.2Hz, CH2), 2.41 (1H, t, J=8.0Hz, CH), 2.58-2.68 (3H, m, CH2+ CH), 3.42 (1H, m, CH), 3.64 (3H, s, CH3), 3.89-4.00 (1H, m, CH), 4.03-4.15 (1H, m, CH), 5.07-5.10 (1H, m, CH), 5.58-5.67 (2H, m, CH2), 6.74-6.78 (1H, m, ArH), 6.94 (2H, t, J= 7.2Hz, ArH);MS (ESI, m/z): 413 [M+H]+
The preparation of 19. Ⅺ beraprost sodium of embodiment
In 100ml single port bottle, Ⅹ 240mg (0.06mmol comes from embodiment 18) is added and is dissolved in 24mL methanol, is added The NaOH aqueous solution of 6mL1mol/L, 30 DEG C are stirred to react 18h.10mL water is added, after concentration, uses 0.1mol/L under ice bath HCl tune pH to 4, ethyl acetate extraction, saturated common salt water washing, anhydrous sodium sulfate dries, filters, after concentration, through silica gel column layer Analyse compound 180mg (0.45mmol) is dissolved in 10mL tri-distilled water by white solid, be added 0.45mL 1mol/L NaOH it is molten Liquid is stirred to react 30min under ice bath, and pH is 7~8 at this time, and beraprost sodium 175mg, molar yield: 92.6% is lyophilized to obtain.It is pure Degree 99%.1H-NMR (d-DMSO, 400MHz) δ 0.92 (3H, d, J=6.4Hz, CH3), 1.57-1.79 (8H, m, CH3+2CH2+ CH), 1.98-2.05 (1H, m, CH), 2.13-2.21 (4H, m, 2CH2), 2.24-2.30 (1H, m, CH), 3.70-3.82 (2H, M, CH2), 4.72-4.79 (2H, m, 2CH), 5.01-5.06 (1H, m, CH), 5.43-5.48 (1H, m, CH=CH), 5.61- 5.67 (1H, m, CH=CH), 6.73 (1H, t, J=7.6Hz, ArH), 6.91-6.93 (2H, m, ArH);MS (ESI, m/z): 399 [M-Na+H]+。
In conclusion the present invention effectively overcomes various shortcoming in the prior art and has high industrial utilization value.
The above-described embodiments merely illustrate the principles and effects of the present invention, and is not intended to limit the present invention.It is any ripe The personage for knowing this technology all without departing from the spirit and scope of the present invention, carries out modifications and changes to above-described embodiment.Cause This, institute is complete without departing from the spirit and technical ideas disclosed in the present invention by those of ordinary skill in the art such as At all equivalent modifications or change, should be covered by the claims of the present invention.

Claims (41)

1. a kind of intermediate, which is characterized in that the structure of the intermediate is as shown in general formula I-1:
Wherein, R1Selected from benzyl, t-butyldimethylsilyi or tert-butyldiphenylsilanyl;X is selected from Br or Cl.
2. intermediate as described in claim 1, which is characterized in that the intermediate is selected from the group compound:
3. a kind of intermediate, which is characterized in that the structure of the intermediate is as shown in general formula I-2:
Wherein, R1Selected from benzyl, t-butyldimethylsilyi or tert-butyldiphenylsilanyl;R3Selected from acetyl group or to first Benzenesulfonyl;X is selected from Br or Cl.
4. intermediate as claimed in claim 3, which is characterized in that the intermediate is selected from the group compound:
5. a kind of intermediate, which is characterized in that the structural formula of the intermediate is as shown in Formulas I -3:
6. a kind of preparation method of intermediate as claimed in claim 1 or 2, which is characterized in that by Formula II compound and formula III Under the effect of the catalyst, reaction prepares compound, and reaction equation is as follows:
7. the preparation method of intermediate as claimed in claim 6, which is characterized in that Formula II compound, catalyst and formula III The molar ratio for closing object is 1:1~1.2:1.2~3.
8. the preparation method of intermediate as claimed in claim 6, which is characterized in that the catalyst is n-BuLi or Zhong Ding Base lithium.
9. the preparation method of intermediate as claimed in claim 6, which is characterized in that Formula II compound is dissolved in organic solvent, Catalyst is added dropwise under inert gas protection in cooling, and the organic solution of formula III compound is then added dropwise, and reaction prepares formula I-1 compound.
10. the preparation method of the intermediate as described in claim 6 or 9, which is characterized in that further include point of -1 compound of Formulas I From purification step: heating up after reaction, saturated ammonium chloride solution is added, water is then added, and be extracted with ethyl acetate, separate Organic phase is obtained, then with after saturated common salt water washing, is dried, is filtered with anhydrous sodium sulfate, be concentrated under reduced pressure, obtain Formulas I- 1 compound.
11. the preparation method of intermediate as claimed in claim 9, which is characterized in that the body of organic solvent and Formula II compound Product is than being 8~15:1.
12. the preparation method of intermediate as claimed in claim 9, which is characterized in that the organic solution of the formula III compound Middle organic solvent is tetrahydrofuran, toluene or ether.
13. the preparation method of intermediate as claimed in claim 9, which is characterized in that the reaction time is 10 after catalyst is added dropwise ~30 minutes.
14. the preparation method of intermediate as claimed in claim 9, which is characterized in that the organic solution of formula III compound is added dropwise The reaction time is 10~60 minutes afterwards.
15. the preparation method of intermediate as claimed in claim 9, which is characterized in that the organic solvent is tetrahydrofuran, first Benzene or ether.
16. the preparation method of intermediate as claimed in claim 9, which is characterized in that the temperature that is cooled to is -60~-80 ℃。
17. a kind of preparation method of intermediate as described in claim 3 or 4, which is characterized in that by -1 compound of Formulas I through second Acylated or tosylation prepares, and reaction equation is as follows:
18. the preparation method of intermediate as claimed in claim 17, which is characterized in that the acylating agent is for acetic anhydride or to first Benzene sulfonyl chloride.
19. the preparation method of intermediate as claimed in claim 17, which is characterized in that reaction temperature is 20~50 DEG C.
20. the preparation method of intermediate as claimed in claim 17, which is characterized in that the reaction time is 8~24 hours.
21. the preparation method of intermediate as claimed in claim 17, which is characterized in that -1 compound of Formulas I is dissolved in organic solvent In, acylating agent is added, adds 4-dimethylaminopyridine, reaction prepares -2 compound of Formulas I.
22. the preparation method of intermediate as claimed in claim 21, which is characterized in that -1 compound of Formulas I, organic solvent, acyl The molar ratio of agent and 4-dimethylaminopyridine is 1:5~10:2~5:0.1~2.
23. the preparation method of the intermediate as described in claim 17 or 21, which is characterized in that further include -2 compound of Formulas I Purification procedures: cooling down after reaction, water is added, and be extracted with dichloromethane, and separation obtains organic phase, then with saturation It after brine It, is dried with anhydrous sodium sulfate, filters, obtain -2 compound of Formulas I.
24. the preparation method of intermediate as claimed in claim 21, which is characterized in that the organic solvent is pyridine.
25. a kind of preparation method of intermediate as claimed in claim 5, which is characterized in that add hydrogen by -2 compound for catalysis of Formulas I It prepares, reaction equation is as follows:
26. the preparation method of intermediate as claimed in claim 25, which is characterized in that the reaction time is 3~18 hours.
27. the preparation method of intermediate as claimed in claim 25, which is characterized in that reaction relative pressure is 1~5MPa.
28. the preparation method of intermediate as claimed in claim 25, which is characterized in that -2 compound of Formulas I is dissolved in organic solvent In, anhydrous sodium acetate and catalyst is added, hydrogen hydrogenation is added to prepare -3 compound of Formulas I.
29. the preparation method of intermediate as claimed in claim 28, which is characterized in that -2 compound of Formulas I, anhydrous sodium acetate, The molar ratio of catalyst is 1:2~5:0.1~0.5.
30. the preparation method of intermediate as claimed in claim 28, which is characterized in that the catalyst is 5% or 10% palladium Carbon.
31. the preparation method of the intermediate as described in claim 25 or 28, which is characterized in that further include -3 compound of Formulas I Purification procedures: filtering out catalyst after reaction, and organic phase is concentrated, and water is added, and be extracted with ethyl acetate, and separation obtains Organic phase is dried then with after saturated common salt water washing with anhydrous sodium sulfate, is filtered, is concentrated under reduced pressure to give -3 chemical combination of Formulas I Object.
32. the preparation method of intermediate as claimed in claim 28, which is characterized in that the organic solvent is selected from methanol, second One of alcohol, isopropanol, ethyl acetate and tetrahydrofuran are a variety of.
33. a kind of preparation method of formula IV compound, which is characterized in that including step d): being obtained by the preparation of -3 compound oxidation of Formulas I Formula IV compound is obtained, reaction equation is as follows:
34. the preparation method of formula IV compound as claimed in claim 33, which is characterized in that the reaction time is 1~5 hour.
35. the preparation method of formula IV compound as claimed in claim 33, which is characterized in that -3 compound of Formulas I is dissolved in second In nitrile and saturation potassium dihydrogen phosphate aqueous solution, tetramethyl piperidine, aqueous sodium hypochlorite solution and sodium chlorite is added, reaction preparation obtains Obtain formula IV compound.
36. the preparation method of formula IV compound as claimed in claim 35, which is characterized in that -3 compound of Formulas I, acetonitrile, phosphorus Acid dihydride potassium, tetramethyl piperidine, sodium hypochlorite sodium chlorite molar ratio be 1:5~20:5~20:0.1~0.5:1~3:1~ 3。
37. the preparation method of formula IV compound as claimed in claim 35, which is characterized in that the concentration of aqueous sodium hypochlorite solution It is 6~14.5%.
38. the preparation method of formula IV compound as claimed in claim 35, which is characterized in that the concentration of sodium chlorite be 80~ 100%.
39. the preparation method of the formula IV compound as described in claim 33 or 35, which is characterized in that further include formula IV compound Purification procedures: water is added after reaction, and is extracted with ethyl acetate, separation obtains organic phase, then successively with full It after hypo solution, water and saturated common salt water washing, is dried with anhydrous sodium sulfate, filters, be concentrated under reduced pressure to give Formula IV compound.
40. the preparation method of formula IV compound as claimed in claim 33, which is characterized in that the preparation method is in step d) Before further include following steps:
Step a): under the effect of the catalyst by Formula II compound and formula III compound, reaction prepares -1 compound of Formulas I, Its reaction equation is as follows:
Step b): -1 compound of Formulas I is prepared into -2 compound of Formulas I, reactional equation through acetylation or tosylation Formula is as follows:
Step c): hydrogen is added to prepare -3 compound of Formulas I -2 compound for catalysis of Formulas I, reaction equation is as follows:
Wherein, R1Selected from benzyl, t-butyldimethylsilyi or tert-butyldiphenylsilanyl;R3Selected from acetyl group or to first Benzenesulfonyl;X is selected from Br or Cl.
41. as intermediate described in any one of claim 1 to 5 is used to prepare beraprost and its salt.
CN201610851108.0A 2016-09-26 2016-09-26 A kind of intermediate and its preparation method and application Active CN106632372B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610851108.0A CN106632372B (en) 2016-09-26 2016-09-26 A kind of intermediate and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610851108.0A CN106632372B (en) 2016-09-26 2016-09-26 A kind of intermediate and its preparation method and application

Publications (2)

Publication Number Publication Date
CN106632372A CN106632372A (en) 2017-05-10
CN106632372B true CN106632372B (en) 2019-04-02

Family

ID=58853880

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610851108.0A Active CN106632372B (en) 2016-09-26 2016-09-26 A kind of intermediate and its preparation method and application

Country Status (1)

Country Link
CN (1) CN106632372B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084856A1 (en) * 1982-01-20 1983-08-03 Toray Industries, Inc. 5,6,7-Trinor-4, 8-inter-m-phenylene prostaglandin I2 derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084856A1 (en) * 1982-01-20 1983-08-03 Toray Industries, Inc. 5,6,7-Trinor-4, 8-inter-m-phenylene prostaglandin I2 derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Catalytic asymmetric formal synthesis of beraprost;Yusuke Kobayashi et al.;《Beilstein J. Org. Chem.》;20151218;第11卷;第2654–2660页,第2655页Scheme 1,第2658页Scheme 4
贝前列素钠的合成及工艺研究;侯大龙;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20150815;第E079-36页,正文第11页路线2.1,第19页第2.3.2.2-2.3.2.3节

Also Published As

Publication number Publication date
CN106632372A (en) 2017-05-10

Similar Documents

Publication Publication Date Title
CN106478572B (en) A kind of preparation method of beraprost and its salt
JP6054935B2 (en) Intermediates for the synthesis of benzoindene prostaglandins and their preparation
Bravo et al. New fluorinated chiral synthons
KR0149508B1 (en) 3-aryl oxazolidinone derivatives, their preparation and their therapeutical use
US6730803B2 (en) Synthetic intermediate for epothilone derivative and production method thereof
CN103787942A (en) Intermediate for preparing lubiprostone, preparation method of intermediate and method for preparing lubiprostone through intermediate
CN106632372B (en) A kind of intermediate and its preparation method and application
EP0295880A1 (en) Substituted cyclic ketones, substituted cyclic enones, and process for producing the same
JPS6247190B2 (en)
CN105732648A (en) Nitrogen heterocyclic ring compound of pyrrolofuran and synthetic method
JP2000510479A (en) Process for producing butylthio-isoquinoline and intermediates thereof
JPH0428268B2 (en)
JP5448420B2 (en) Hexahydroxydiphenoyl compound
CN105566150B (en) The preparation method of aliskiren
WO2020155613A1 (en) Preparation method for ecteinascidin compound and intermediate thereof
EP2861572B1 (en) Improved process for the preparation of 2-substituted-2-(6-(substituted)-7-methylbenzo[d][1,3]dioxol-4-yl)acetic acid derivatives
CN103183591B (en) 4 '-dialkoxymethyl bis cyclohexane-4-base methyl alcohol and manufacture method thereof
CN102643276B (en) Immunosuppressive agent FR901483 intermediate and synthetic method thereof
JP3134786B2 (en) 2-Azabicyclo [3.3.0] octane derivatives, their production and optical resolution of diols or amino alcohols
JPH08245612A (en) Production of 2-deoxy-2,2-difluoro-beta-d-libopentopyranose
CN117466953A (en) Preparation method of natural product emmbeloside A
JPH078815B2 (en) Optically Active 2-Methylenecyclopentanone Derivatives, Intermediates Thereof, and Their Production Process
JP2893473B2 (en) Process for producing (+)-equilenin and intermediate
CN118027091A (en) Preparation method of treprostinil and intermediate thereof
CN101544540B (en) (R)-2-methyl-5,5-diphenyl-4-amylene-1-ol derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant